Pharmaceutical firm Lupin today said it has received final approval from US health regulator to market the generic?version?of Mycobutin?capsules of Pharmacia?and?Upjohn?Company that are used while treating advance HIV infection. (Read: Indian pharma to reach new heights but will it be able to maintain quality?) The approval from the US Food and Drug Administration is for Rifabutin?Capsules?USP in strength of 150?mg said Lupin in a statement. 'Lupin Pharmaceuticals Inc (LPI) the company?s US subsidiary would commence marketing the product shortly' it said further. (Read: Is the ban of pioglitazone justified? (Expert interview)) The drug is used for prevention of disseminated Mycobacterium
